| Q37296603 | A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 |
| Q38004067 | Anti-angiogenic therapies for malignant pleural mesothelioma |
| Q90056612 | Antiangiogeneic Strategies in Mesothelioma |
| Q37328307 | Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. |
| Q35057364 | Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q38672944 | Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases. |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q36758593 | Emerging drugs for mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q49996923 | Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications |
| Q34293068 | Investigational approaches for mesothelioma |
| Q89622483 | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future |
| Q83412919 | Malignant pleural mesothelioma |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q36097706 | Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q35129535 | Novel therapies in phase II and III trials for malignant pleural mesothelioma. |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q52672891 | Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. |
| Q94570184 | Thalidomide for Patients with β-Thalassemia: A Multicenter Experience |
| Q43800002 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |